[CAS NO. 1035979-44-2] Sarecycline hydrochloride
PRODUCTS SPECIFICATIONS [1035979-44-2]
DESCRIPTION [1035979-44-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 523.96 |
| Molecular Formula | C24H30ClN3O8 |
| SMILES | [H]Cl.O[C@]12[C@](C[C@@]3([H])C(C(C4=C(O)C=CC(CN(C)OC)=C4C3)=O)=C2O)([H])[C@@H](C(O)=C(C1=O)C(N)=O)N(C)C |
2 Publications Citing Use of MCE
Summary
Sarecycline hydrochloride is a narrow-spectrum tetracycline-class antibiotic . Sarecycline hydrochloride possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of Cutibacterium acnes . Sarecycline hydrochloride interferes with tRNA accommodation and tethers mRNA to the 70S ribosome [1] [2] [3] .
IC50 & Target
|
Tetracycline |
In Vitro
Sarecycline inhibits 55 clinical isolates of
C. acnes
, and the MIC values for Sarecycline ranged from 0.5 to 16 µg/ml; the MIC
50
was 0.5 µg/ml, and the MIC
90
was 4 µg/ml. Sarecycline, exhibits activity against the macrolide-resistant organisms
[1]
.
Sarecycline hydrochloride exhibits minimal activity against enteric aerobic Gram-negative bacteria
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Sarecycline hydrochloride (0.33-9 mg/kg; i.v.) show potent activity against S. aureus in a murine neutropenic thigh infection model [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female SD-1 mice (A murine neutropenic thigh wound infection model) [1] |
| Dosage: | 0.33, 1, 3, or 9 mg/kg |
| Administration: | Intravenously |
| Result: | Achieved a 2-log10 reduction in the bacterial burden in the thigh at a dose comparable to that of doxycycline, with ED50s of 8.23 and 8.32 mg/kg, respectively. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05010538 | Angela Moore|Almirall, SAS|Arlington Research Center |
Acne Vulgaris
|
March 9, 2021 | |
| NCT02320149 | Almirall, S.A.|Allergan |
Acne Vulgaris
|
December 18, 2014 | Phase 3 |
| NCT02413346 | Almirall, S.A.|Allergan |
Acne Vulgaris
|
March 20, 2015 | Phase 3 |
| NCT02322866 | Almirall, S.A.|Allergan |
Acne Vulgaris
|
December 3, 2014 | Phase 3 |
| NCT04820673 | Almirall, S.A. |
Acne Vulgaris
|
May 24, 2021 | |
| NCT04555525 | Derm Research, PLLC |
Acne Rosacea
|
April 15, 2019 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 100 mg/mL ( 190.85 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9085 mL | 9.5427 mL | 19.0854 mL |
| 5 mM | 0.3817 mL | 1.9085 mL | 3.8171 mL |
| 10 mM | 0.1909 mL | 0.9543 mL | 1.9085 mL |
References
- [1] Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob Agents Chemother. 2018;63(1):e01297-18. Published 2018 Dec 21.
- [2] Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14(14):1235-1242.
- [3] Batool Z, et al. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome. Proc Natl Acad Sci U S A. 2020;117(34):20530-20537.